We propose that daily torpor in AD-relevant transgenic mouse models (e.g., htau mice with or without amyloid pathology) can be used to better model processes involved in human tau pathology, with the prospect to uncover disease-relevant accumulation and clearance mechanisms and potential intervention targets therein. Here, MAPT is linked to amyloidosis.